These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1953184)

  • 21. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
    Kaye KS; Kanafani ZA; Dodds AE; Engemann JJ; Weber SG; Carmeli Y
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2192-6. PubMed ID: 16723582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility of Pseudomonas aeruginosa to fluoroquinolones following four years of use in a tertiary care hospital.
    Shalit I; Haas H; Berger SA
    J Antimicrob Chemother; 1992 Aug; 30(2):149-52. PubMed ID: 1399924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
    Willcox MD
    Clin Exp Optom; 2011 Mar; 94(2):161-8. PubMed ID: 21083760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.
    Dellamonica P; Bernard E; Etesse H; Garraffo R; Drugeon HB
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1024-30. PubMed ID: 2515961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
    Chodosh S
    Am J Med; 1991 Dec; 91(6A):93S-100S. PubMed ID: 1662900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F; Yuluğ N
    Mikrobiyol Bul; 1988; 22(3):187-92. PubMed ID: 3252111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
    McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
    Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
    [No Abstract]   [Full Text] [Related]  

  • 35. Modulation of biofilms of Pseudomonas aeruginosa by quinolones.
    Yassien M; Khardori N; Ahmedy A; Toama M
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2262-8. PubMed ID: 8619580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinolone therapy in the prevention of mortality after irradiation.
    Brook I; Elliott TB
    Radiat Res; 1991 Oct; 128(1):100-3. PubMed ID: 1924719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinolones in the treatment of bronchopulmonary infections.
    Thys JP
    Rev Infect Dis; 1988; 10 Suppl 1():S212-7. PubMed ID: 3279495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
    Naumann P; Dopp C
    Internist (Berl); 1989 Jan; 30(1):20-31. PubMed ID: 2646237
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin.
    Brook I; Elliott TB; Ledney GD
    Radiat Res; 1990 May; 122(2):215-7. PubMed ID: 2186431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.